What should I pay attention to when using teriparatide injection?

Teriparatide injection (Teriparatide), as a drug used to treat osteoporosis, can reduce the risk of fractures by promoting bone formation and increasing bone density. However, when using teriparatide injection, patients need to pay attention to a series of things to ensure the safe and effective use of the drug. Here are a few key areas to pay special attention to while using teriparatide.

1. Blood calcium monitoring

Teriparatide injection may cause hypercalcemia (increased calcium levels in the blood), so blood calcium levels need to be monitored regularly during treatment. Particularly during the initial stages of treatment and during drug dose adjustments, patients' blood calcium levels should be tested monthly. If the blood calcium level is found to be abnormally elevated, the drug dose should be adjusted promptly or treatment should be suspended. Symptoms of hypercalcemia include nausea, vomiting, thirst, constipation, muscle weakness, and fatigue. If these symptoms occur, seek medical attention immediately. Blood calcium levels should be maintained within the normal range to avoid negative effects on organs such as the heart and kidneys.

2. Observation of allergic reactions

Although allergic reactions are rare during use of teriparatide, some patients may still experience allergic reactions. Common allergy symptoms include rash, itching, urticaria, and more severe dyspnea, laryngeal edema, etc. If patients develop allergic symptoms after using the drug, they should stop taking the drug immediately and seek emergency medical help. Allergic reactions generally occur when a drug is first used, so before starting treatment, patients should inform their doctor if they have a history of allergies, especially to other drugs, injections, or biological agents.

3. Fracture risk and treatment duration

Teriparatide injection is commonly used to treat osteoporosis, especially in patients who have experienced a fracture or are at higher risk for fracture. However, its use is usually short-term, with treatment periods ranging from 1 to 2 years. Long-term use may increase the risk of side effects, so after treatment expires, the patient's bone density and fracture risk are usually assessed and treatment options adjusted accordingly. After treatment ends, patients may turn to other drugs (such as bisphosphonates, selective estrogen receptor modulators, etc.) for long-term management of osteoporosis.

4. Kidney function monitoring

Teriparatide should be used with caution in patients with renal impairment because the drug is primarily metabolized by the kidneys. Although teriparatide can be used in patients with mild and moderate renal impairment, the drug should be avoided in patients with severe renal impairment. If the patient already has renal insufficiency, especially if the renal disease is in a severe stage, extra caution should be taken when using teriparatide and renal function should be checked regularly. If the patient develops kidney problems or abnormal blood calcium levels during treatment, he or she should communicate with the doctor in time to adjust the treatment plan.

5. Assessment of bone tumor risk

There is a potential link between teriparatide and bone tumors such as osteosarcoma. Although this risk is clinically very low, animal experiments have shown that long-term use of teriparatide may increase the incidence of bone tumors. Therefore, this drug should be avoided in those with a history of bone tumors, a family history of osteosarcoma, or those undergoing cancer treatment. If a patient has any signs of bone tumors, a thorough evaluation is required before using teriparatide, and a doctor's decision on whether to use the drug will be made based on the patient's specific circumstances.

6. Contraindicated during pregnancy and lactation

The safety of teriparatide injection in pregnant and lactating women has not been fully proven, so these two groups should generally not use the drug. Research in animal experiments shows that teriparatide may have adverse effects on the fetus, so women during pregnancy should avoid using this drug. During lactation, it is not known whether it is excreted in breast milk, so lactating women should also avoid using this drug. If patients plan to become pregnant or are pregnant, they should communicate with their doctor before starting treatment to choose an appropriate treatment plan.

7. The impact of patient comorbidities

When using teriparatide, the presence of comorbidities may affect the use of the drug. For example, people with diabetes need to pay special attention to changes in blood sugar levels, especially when taking teriparatide. If a patient has diabetes, blood sugar levels may fluctuate after taking teriparatide, so blood sugar changes need to be monitored closely. For other patients with severe cardiovascular disease, a history of allergies, or digestive system problems, they should also use this drug with caution and adjust their treatment under the guidance of a doctor.

8. Injection technology and patient self-management

Teriparatide injection is usually a subcutaneous injection, and patients can inject it themselves under the guidance of a doctor. To ensure the accuracy and safety of injections, patients should learn correct injection techniques before use. The injection site is usually the anterolateral thigh or abdomen. Avoid using the same site repeatedly during injection to reduce local reactions. Before use, patients should check the outer packaging and syringe of the drug to ensure that the drug has not deteriorated or been damaged. If any abnormalities are found, discontinue use and contact a doctor.

9. Drug interactions

Teriparatide injection may interact with other drugs, especially those that affect calcium, phosphorus, or vitamin D metabolism. For example, the risk of hypercalcemia may be increased when using calcium-containing supplements, vitamin D, or certain diuretics. During treatment with teriparatide, patients should inform their doctor of all medications they are taking, including prescription drugs, over-the-counter drugs, and any herbal or supplements, so that their doctor can evaluate and adjust possible drug interactions.

During the use of teriparatide injection, patients need to pay attention to many aspects to ensure safe and effective treatment. Regular monitoring of blood calcium levels, observation of possible allergic reactions, assessment of kidney function and bone tumor risk, avoidance of use during pregnancy and lactation, correct injection technique, and drug interactions are all important aspects to ensure the smooth progress of teriparatide treatment. Patients should follow the doctor's instructions, conduct regular examinations, and maintain communication with the doctor to ensure the safety and effectiveness of treatment.